What is Nexien Biopharma's earnings per share (EPS)?

Nexien Biopharma (NXEN) reported diluted earnings per share of $0.00 for fiscal year 2024. This represents a 100.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Nexien Biopharma Financials

NXEN

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2025 Currency USD FYE June

This page shows Nexien Biopharma (NXEN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 16/100

Based on FY2024 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Nexien Biopharma's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage

Nexien Biopharma carries a low D/E ratio of -1.01, meaning only $-1.01 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 99/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Nexien Biopharma's current ratio of 0.01 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

N/A

EPS (Diluted)

$0.00

YoY+100.0%

Nexien Biopharma earned $0.00 per diluted share (EPS) in fiscal year 2024. This represents an increase of 100.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$4K

YoY-88.1%

5Y CAGR-50.9%

Nexien Biopharma held $4K in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

70M

YoY+10.1%

5Y CAGR+5.7%

Nexien Biopharma had 70M shares outstanding in fiscal year 2024. This represents an increase of 10.1% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

Nexien Biopharma invested $0 in research and development in fiscal year 2024.

Share Buybacks

N/A

Capital Expenditures

N/A

NXEN Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$0	$0	$0	$0	N/A	$64K
SG&A Expenses	N/A	N/A	$531K	N/A	N/A	N/A
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	N/A	N/A	N/A	N/A	$33	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	$0.00+100.0%	$-0.010.0%	$-0.01	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$0	$0	$0	N/A	$0	$0	$0	N/A
SG&A Expenses	$5K	N/A	$3K	N/A	$9K+18.8%	$8K-83.2%	$46K	N/A
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$30K	N/A	N/A	N/A	-$53K	N/A	-$75K	N/A
EPS (Diluted)	$0.00	$0.00	$0.00	N/A	$0.00	$0.00+100.0%	$-0.00	N/A

NXEN Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$4K-90.3%	$43K-65.4%	$125K+387.5%	$26K+12.1%	$23K-92.7%	$311K
Current Assets	$4K-90.3%	$43K-65.4%	$125K+387.5%	$26K+12.1%	$23K-92.7%	$311K
Cash & Equivalents	$4K-88.1%	$35K-69.9%	$117K+548.0%	$18K+67.3%	$11K-92.6%	$146K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$365K+23.8%	$295K+21.9%	$242K+515.8%	$39K+34.9%	$29K-34.9%	$45K
Current Liabilities	$365K+23.8%	$295K+21.9%	$242K+515.8%	$39K+34.9%	$29K-34.9%	$45K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$361K-43.3%	-$252K-114.3%	-$118K-753.8%	-$14K-116.4%	-$6K-102.4%	$266K
Retained Earnings	-$11.5M-2.1%	-$11.3M-3.3%	-$10.9M-6.1%	-$10.3M-22.0%	-$8.4M-46.3%	-$5.8M

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Total Assets	$8K+534.4%	$1K-73.6%	$5K+18.4%	$4K-70.7%	$14K+444.7%	$3K-88.1%	$22K-48.9%	$43K
Current Assets	$8K+534.4%	$1K-73.6%	$5K+18.4%	$4K-70.7%	$14K+444.7%	$3K-88.1%	$22K-48.9%	$43K
Cash & Equivalents	$8K+534.4%	$1K-73.6%	$5K+18.4%	$4K-58.4%	$10K+284.4%	$3K-85.5%	$18K-48.6%	$35K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$459K+8.2%	$424K+6.9%	$397K+8.6%	$365K+7.6%	$340K+7.2%	$317K+1.3%	$313K+6.0%	$295K
Current Liabilities	$459K+8.2%	$424K+6.9%	$397K+8.6%	$365K+7.6%	$340K+7.2%	$317K+1.3%	$313K+6.0%	$295K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$451K-6.6%	-$423K-7.9%	-$392K-8.4%	-$361K-11.1%	-$325K-3.5%	-$314K-8.0%	-$291K-15.4%	-$252K
Retained Earnings	-$11.6M-0.3%	-$11.6M-0.3%	-$11.6M-0.3%	-$11.5M-0.8%	-$11.4M-0.5%	-$11.4M-0.2%	-$11.4M-0.7%	-$11.3M

NXEN Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	N/A	-$82K-8.8%	-$75K+17.2%	-$91K	N/A	-$643K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	-$30K
Financing Cash Flow	N/A	N/A	$174K+77.6%	$98K+716.7%	$12K	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Operating Cash Flow	-$13K	N/A	-$9K+15.2%	-$11K+48.1%	-$21K	N/A	-$17K+10.4%	-$19K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$20K	N/A	$10K+100.0%	$5K	N/A	N/A	N/A	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

NXEN Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	N/A	N/A	N/A	N/A	N/A	N/A
Current Ratio	0.01-0.1	0.15-0.4	0.51-0.1	0.65-0.1	0.78-6.2	6.94
Debt-to-Equity	-1.01+0.2	-1.17+0.9	-2.06+0.8	-2.85+1.7	-4.58-4.7	0.17
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-363.2%	N/A	N/A	N/A	-372.6%	N/A	-339.7%	N/A
Current Ratio	0.02+0.0	0.000.0	0.010.0	0.01-0.0	0.04+0.0	0.01-0.1	0.07-0.1	0.15
Debt-to-Equity	-1.02-0.0	-1.000.0	-1.010.0	-1.01+0.0	-1.04-0.0	-1.01+0.1	-1.08+0.1	-1.17
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$361K), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.01), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Adastra Holdings Ltd XTXXF

$39K

Rimrock Gold RMRK

$865K

Kaya Hldgs Inc KAYS

$11.0M

Pharmadrug Inc LMLLF

$738K

Cann American Corp CNNA

$994K

Frequently Asked Questions

What are Nexien Biopharma's total assets?

Nexien Biopharma (NXEN) had $4K in total assets as of fiscal year 2024, including both current and long-term assets.

How many shares does Nexien Biopharma have outstanding?

Nexien Biopharma (NXEN) had 70M shares outstanding as of fiscal year 2024.

What is Nexien Biopharma's current ratio?

Nexien Biopharma (NXEN) had a current ratio of 0.01 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.

What is Nexien Biopharma's debt-to-equity ratio?

Nexien Biopharma (NXEN) had a debt-to-equity ratio of -1.01 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

Why is Nexien Biopharma's debt-to-equity ratio negative or unusual?

Nexien Biopharma (NXEN) has negative shareholder equity of -$361K as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

How financially healthy is Nexien Biopharma?

Nexien Biopharma (NXEN) scores 16 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.